<DOC>
	<DOCNO>NCT00117182</DOCNO>
	<brief_summary>The purpose study determine whether Aridol ( mannitol ) challenge test predict response treatment inhaled corticosteroid COPD subject . Subjects undergo Aridol test 3 month treatment inhaled corticosteroid . The effect lung function quality life measure correlated Aridol test result .</brief_summary>
	<brief_title>Aridol Challenge Tool Predict Treatment Response Inhaled Corticosteroids COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>Diagnosis COPD ( history , spirometry , symptom include chronic cough and/or shortness breath bad exertion and/or excess sputum production ) Aged 45 80 year Have prebronchodilator FEV1 &gt; 1.4 litre least 60 % predict height , age gender postbronchodilator FEV1 &lt; 80 % predict height , age gender Postbronchodilator FEV1/FVC &lt; 70 % ≥ 10 pack year smoke history As determined investigator , capable willing : perform technique necessary measure lung function ; administer dry powder mannitol . Are capable , give informed consent , participate study accordance local regulation . The subject must stable clinical condition time , period 14 day prior , recruitment study . Stable clinical condition define lack : change sputum production ( volume , colour , consistency ) ; increase cough ; worsen dyspnoea ; increase malaise , fatigue lethargy ; reduction exercise tolerance ; fever ; antibiotic treatment ( respiratory infection ) . Investigators , site personnel directly affiliate study , immediate family . Immediate family define spouse , parent , child sibling , whether biologically legally adopt . Subjects receive treatment inhaled corticosteroid ( include combination therapy , e.g . Seretide® , Symbicort® ) oral corticosteroid within last 6 week . Subjects exacerbation chest infection within 2 week prior study . Subjects receive antibiotic treatment respiratory infection . Known diagnosis asthma allergic rhinitis . Myocardial infarction six month prior enrolment . Cerebral vascular accident six month prior enrolment . Ocular surgery three month prior enrolment . Abdominal surgery three month prior enrolment . Active tuberculosis ( TB ) . Lung cancer malignancy , consider investigator contraindication participate study . Lung disease COPD ( e.g . bronchiectasis ) . Uncontrolled insulindependant noninsulin dependant diabetes , i.e . &gt; 10 % HbA1c . Female subject reproductive capability , use reliable form contraception Inability obtain informed consent subject subject 's authorised representative . Subjects participate another investigative drug study parallel , within 4 week , study entry . Known intolerance mannitol . Uncontrolled hypertension systolic blood pressure ( BP ) &gt; 200 mmHg diastolic BP &gt; 100 mmHg . Planned pulmonary rehabilitation . Have major abdominal , chest brain surgery three month prior enrolment . Have know cerebral , aortic abdominal aneurysm .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>